Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for dementia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies Identification of individuals at high risk of dementia is essential for development of prevention strategies, but reliable tools are lacking for risk stratification in the population. The authors developed and validated a prediction model to calculate the 10-year absolute risk of developing dementia in an aging population.In a large, prospective population-based (...) cohort, data were collected on demographic, clinical, neuropsychological, genetic, and neuroimaging parameters from 2,710 nondemented individuals age 60 or older, examined between 1995 and 2011. A basic and an extended model were derived to predict 10-year risk of dementia while taking into account competing risks from death due to other causes. Model performance was assessed using optimism-corrected C-statistics and calibration plots, and the models were externally validated in the Dutch population
Peri-operative care of people with dementia Guidelines Peri-operative care of people with dementia February 2019Guidelines Guidelinesfortheperi-operativecareofpeoplewithdementia GuidelinesfromtheAssociationofAnaesthetists S.White, 1 R.Grif?ths, 2 M.Baxter, 3 T.Beanland, 4 J.Cross, 5 J.Dhesi, 6 A.B.Docherty, 7 I.Foo, 8 G.Jolly, 9 J.Jones, 10 I.K.Moppett, 11 E.Plunkett 12 andK.Sachdev 13 1ConsultantAnaesthetist,RoyalSussexCountyHospital,Brighton,UKandco-Chair,AssociationofAnaesthetists (...) 13ConsultantinOlderAdultPsychiatry,HomertonUniversityHospitalNHSFoundationTrust,London,UK Summary Ageing populations have greater incidences of dementia. People with dementia present for emergency and, increasingly, elective surgery, but are poorly served by the lack of available guidance on their peri-operative management, particularly relating to pharmacological, medico-legal, environmental and attitudinal considerations. These guidelines seek to deliver such guidance, by providing information for peri-operative care
Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia National Clinical Guideline No. 21 National Patient Safety Office Oi?g Náisiúnta um Shábháilteacht Othar December 2019This National Clinical Guideline has been developed by a guideline development group convened by the National Dementia Office, to fulfil priority action point 2.3 (...) of the National Dementia Strategy Implementation plan, namely “The Health Service Executive will develop guidance material on the appropriate management of medication for people with dementia, and in particular on psychotropic medication management, and make arrangements for this material to be made available in all relevant settings, including nursing homes”. Using this National Clinical Guideline This National Clinical Guideline applies to people with dementia of any age, and of any type, and in any setting
Promising results from a pilot study to reduce distress in Vietnamese American dementia and memory loss caregivers. This study developed and examined the feasibility of a culturally tailored, evidence-based skill-building program to reduce stress and depression of Vietnamese American dementia caregivers.This pilot randomized controlled trial included pretest and posttest measures using the Center for Epidemiologic Studies-Depression Scale and the Revised Memory and Behavior Problems Checklist (...) . The intervention (n = 30) group participated in a culturally tailored, 4-week Vietnamese-language cognitive-behavioral skills evidenced-based program (Our Family Journey); caregivers in the control condition (n = 30) received dementia-related educational materials (education control condition).Our Family Journey caregivers showed significantly lower somatic scores on the Center for Epidemiologic Studies-Depression Scale and reported lower frequency of care recipients' disruptive behaviors. However, they also
Study protocol of the self-monitoring activity program: Effects of activity on incident dementia. Numerous studies have focused on nonpharmacological interventions on cognitive function and the effects of cognitive function on daily living. However, effects of behavior change techniques that promote physical, cognitive, and social activities on cognitive function and incident dementia in the elderly are yet to be elucidated. In this study, we aimed to design a single-blind, randomized (...) controlled trial to study dementia prevention effects of behavior change techniques, using an accelerometer and a newly developed daily activity booklet in community-living older adults.The study cohort comprised 5390 individuals aged 65 years and older who were randomized into one of the following three groups: accelerometer group (n = 1508), accelerometer and daily activity booklet group (n = 1180), or a control group (n = 2702; vs. accelerometer group [n = 1509] vs. accelerometer and daily activity
Outcomes: Electroconvulsive therapy does not increase the risk of dementia in patients with affective disorders Electroconvulsive therapy does not increase the risk of dementia in patients with affective disorders | Evidence-Based Mental Health Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Electroconvulsive therapy does not increase the risk of dementia in patients with affective disorders Article Text Commentary Outcomes Electroconvulsive therapy does not increase the risk of dementia in patients with affective disorders Pascal Sienaert Correspondence to Professor Pascal Sienaert, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU
Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. There are currently no proven treatments to reduce the risk of mild cognitive impairment and dementia.To evaluate the effect of intensive blood pressure control on risk of dementia.Randomized clinical trial conducted at 102 sites in the United States and Puerto Rico among adults aged 50 years or older with hypertension but without diabetes or history of stroke. Randomization began (...) on November 8, 2010. The trial was stopped early for benefit on its primary outcome (a composite of cardiovascular events) and all-cause mortality on August 20, 2015. The final date for follow-up of cognitive outcomes was July 22, 2018.Participants were randomized to a systolic blood pressure goal of either less than 120 mm Hg (intensive treatment group; n = 4678) or less than 140 mm Hg (standard treatment group; n = 4683).The primary cognitive outcome was occurrence of adjudicated probable dementia
France has delisted anti-dementia agents MED CHECK - TIP December 2018/ Vol.4 No.12 · Page 29 -The Informed Prescriber C N o 12 M ED HECK D e ce m b e r 2 0 1 8 Dying Cochrane: Could it be resuscitated? Herpes zoster subunit vaccine Shingrix: Baloxavir (Xofluza®) for Influenza: No Value No difference from Tamiflu in efficacy, and suppresses immunity Cochrane review on HPV vaccine should be revised: Due to missing trials, adjuvant toxicity, mortality and healthy user bias Editorial Dying
DementiaDementia - NICE CKS Share Dementia: Summary Dementia is a clinical syndrome of deterioration in mental function which interferes with activities of daily living (ADLs). It affects more than one cognitive domain (for example memory, language, orientation, or judgement) and social behaviour (for example, emotional control or motivation). Early (or young) onset dementia is generally defined as dementia that develops before 65 years of age. Mild cognitive impairment is cognitive impairment (...) that does not fulfil the diagnostic criteria for dementia — for example, only one cognitive domain is affected, or ADLs are not significantly affected. The most common subtypes of dementia include: Alzheimer's disease (50–75%) which often co-exists with vascular dementia. Vascular dementia (up to 20%). Dementia with Lewy bodies (10–15%). Frontotemporal dementia (2%). Modification of specific risk factors (in particular, cardiovascular risk factors such as smoking, diabetes and lack of physical activity
Care of the older person: Evidence that active pain treatment improves sleep quality and quantity in people with depression and dementia Evidence that active pain treatment improves sleep quality and quantity in people with depression and dementia | Evidence-Based Nursing Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence that active pain treatment improves sleep quality and quantity in people with depression and dementia Article Text Commentary Care of the older person Evidence that active pain treatment improves sleep quality and quantity in people with depression and dementia Amelia Swift Statistics from Altmetric.com Commentary on : Blytt KM, Bjorvatn B, Husebo B
Traditional Chinese herbal medicine for vascular dementia. Traditional Chinese herbal medicine (TCHM) is widely used for treating vascular dementia (VaD) in China. Recent studies of a number of TCHMs have demonstrated in vitro biological activity and therapeutic effects in animals, but the published clinical evidence has not been systematically appraised.To evaluate the efficacy and safety of TCHMs listed in either the Chinese Pharmacopoeia (CP) or the Chinese National Essential Drug List (NEDL (...) ) that are used to treat VaD. A secondary aim was to identify promising TCHMs for further clinical research.We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's Specialised Register (on 14 March 2018) and also several Chinese biomedical databases: the Chinese Biological Medicine Database (January 1979 to May 2015), Wanfang database (January 1998 to May 2015), Chongqing VIP Information Co. Ltd or Weipu (January 1998 to May 2015) and the Chinese National Knowledge Infrastructure (January
Agitation in Dementia: Quantifying the effects of antipsychotics Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) February 26, 2018 Agitation in Dementia: Quantifying the effects of antipsychotics Clinical Question: What are the benefits and harms of antipsychotics for agitation in dementia? Bottom Line: A strong placebo effect explains most of the perceived efficacy, with antipsychotics providing little additional improvement over placebo on agitation scales (~3 additional points out of 144). However, 50% improvement in behaviour occurs in ~46% on antipsychotic versus ~33% on placebo. Harms are serious (increased
Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia To examine the effect of 25-hydroxyvitamin D (25(OH)D) levels recommended by Endocrine Society guidelines (>30 ng/mL) on cognition in healthy older African-American women over 3 years.Randomized, double-blind, placebo-controlled clinical trial.Bone Mineral Research Center at New York University Winthrop Hospital.Healthy
A protocol to evaluate the impact of involvement of older people with dementia and age-related hearing and/or vision impairment in a multi-site European research study Involving older people with dementia in research is increasingly recognised as important to ensure that research is relevant and beneficial for older people with dementia. But researchers need to know how best to involve older people with dementia and to be able to show the benefits of involving older people with dementia (...) in dementia research.This paper describes a research plan to explore the involvement of older people with dementia and age-related hearing and/or vision impairment in a European research project investigating the combined impact of dementia with hearing and/or vision impairment. We set up four Research User Groups (RUGs) of older people with dementia with age-related hearing and/or vision impairment and their carers based in the UK, France, Cyprus and Greece to advise our researchers. We provided training
Pre-eclampsia and risk of dementia later in life: nationwide cohort study. To explore associations between pre-eclampsia and later dementia, overall and by dementia subtype and timing of onset.Nationwide register based cohort study.Denmark.All women with at least one live birth or stillbirth between 1978 and 2015.Hazard ratios comparing dementia rates among women with and without a history of pre-eclampsia, estimated using Cox regression.The cohort consisted of 1 178 005 women with 20 352 695 (...) person years of follow-up. Women with a history of pre-eclampsia had more than three times the risk of vascular dementia (hazard ratio 3.46, 95% confidence interval 1.97 to 6.10) later in life, compared with women with no history of pre-eclampsia. The association with vascular dementia seemed to be stronger for late onset disease (hazard ratio 6.53, 2.82 to 15.1) than for early onset disease (2.32, 1.06 to 5.06) (P=0.08). Adjustment for diabetes, hypertension, and cardiovascular disease attenuated
Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study To determine whether antidepressant use is associated with dementia risk.Prospective cohort study.Kaiser Permanente Washington (KPWA), an integrated healthcare delivery system.Community-dwelling individuals aged 65 and older without dementia and with 10 years or more of KPWA enrollment at baseline (N=3,059).Primary exposures were selective serotonin reuptake inhibitors (paroxetine vs other), tricyclic (...) antidepressants, and serotonin antagonist and reuptake inhibitors. Using health plan pharmacy data, we calculated cumulative medication exposure, defined as total standardized daily doses (TSDDs), over rolling 10-year windows. Exposure in the most recent year was excluded to avoid use related to prodromal symptoms. The Cognitive Abilities Screening Instrument was administered every 2 years; low scores triggered clinical evaluation and consensus diagnosis procedures. Dementia risk was estimated according
Modifying the consistency of food and fluids for swallowing difficulties in dementia. People with dementia can have feeding and swallowing difficulties (dysphagia). Modification of the consistency of food or fluids, or both, is a common management strategy. However, diet modification can affect quality of life and may lead to dehydration and malnutrition. Evidence on the benefits and risks of modifying food and fluids is mandatory to improve the care of people with dementia and dysphagia.To (...) determine the effectiveness and adverse effects associated with modifying the consistency of food and fluids in improving oral intake and eliminating aspiration in adults with dysphagia and dementia.We searched ALOIS (the Specialised Register of the Cochrane Dementia and Cognitive Improvement Group), the Cochrane Library, MEDLINE via Ovid SP, Embase via Ovid SP, PsycINFO via Ovid SP, CINAHL via EBSCOhost, LILACS via BIREME, ClinicalTrials.gov and the World Health Organization (WHO) Portal on 9 May 2018
Assessment of dementia Assessment of dementia - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Assessment of dementia Last reviewed: February 2019 Last updated: September 2018 Summary Dementia is a syndrome characterised by an appreciable deterioration in cognition resulting in behavioural problems and impairment in the activities of daily living. Decline in cognition is extensive, often affecting multiple domains (...) of intellectual functioning. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013. Cummings JL, Benson DF. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heinemann; 1992. The prevalence of dementia is approximately 1% at the age of 60 years, and doubles every 5 years, to reach 30% to 50% by the age of 85 years. The majority of cases of dementia have degenerative and vascular causes. Thal LJ